# 2394: hVIVO Secures £6m Influenza Human Challenge Trial Contract

Page: https://stenobird.com/podcast/the-vox-markets-podcast-3914537/2394-hvivo-secures-6m-influenza-human-challenge-trial-contract
Text version: https://stenobird.com/podcast/the-vox-markets-podcast-3914537/2394-hvivo-secures-6m-influenza-human-challenge-trial-contract.md
Podcast: [The Vox Markets Podcast](https://stenobird.com/podcast/the-vox-markets-podcast-3914537)
Published: 2026-05-07T08:58:00+00:00
Episode link: https://audioboom.com/posts/8900463
Audio file: https://dts.podtrac.com/redirect.mp3/audioboom.com/posts/8900463.mp3?modified=1778144305&sid=5051662&source=rss
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-vox-markets-podcast-3914537/episodes/2394-hvivo-secures-6m-influenza-human-challenge-trial-contract
Duration seconds: 355

## Resource

Watch on YouTube Andrew Catchpole, Chief Scientific Officer of hVIVO joins Martin Luke of Vox Markets to discuss hVIVO’s newly signed £6 million influenza human challenge trial contract. Andrew explains how the study will evaluate a prophylactic antiviral treatment using hVIVO’s specialist influenza challenge model, highlighting the speed and efficiency advantages of human challenge trials, the growing focus on antiviral therapies, and why hVIVO continues to attract global clients.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-vox-markets-podcast-3914537/episodes/2394-hvivo-secures-6m-influenza-human-challenge-trial-contract/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-vox-markets-podcast-3914537/2394-hvivo-secures-6m-influenza-human-challenge-trial-contract.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.